Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 July 2021 | Story Lunga Luthuli | Photo Supplied
Fletcher Hiten, Chief Bioanalyst at FARMOVS, next to Aurora.

The Bioanalytical Services Division (BASD) at FARMOVS comprises a group of skilled and passionate scientists involved in the quantification of drugs, metabolites, and biomarkers in various biological matrices. One of their Analytical Science experts, Fletcher Hiten, explains what sets their team apart from the rest.

“Over the past 47 years, we have developed almost 600 validated assay methods. Most of these methods are for the analysis of ‘small’ molecules using chromatographic techniques such as LC-MS/MS, GC-MS, and HPLC, although LC-MS/MS is the technique of choice. New bioanalytical assays are continuously being development and validated in adherence to international regulatory guidelines set by the US-FDA and European Medicines Agency (EMA),” says Hiten.

“Recently, we decided to enhance our capabilities by recruiting exceptional talent. The newest member of the FARMOVS team is Aurora, a SCIEX Triple Quad™ 7500 LC-MS/MS mass analyser. Aurora is Latin for ‘dawn’: the beginning of a new era, especially one considered favourable. The SCIEX 7500 is currently marketed as the most sensitive triple quadrupole mass spectrometer available, allowing for sub-picogram/ml quantification. This means that Aurora will set FARMOVS apart from other clinical research organisations (CROs), creating an exciting and favourable landscape for clients to explore new partners in research.” 

Hiten stated: “If there was ever a time to move your next study to FARMOVS, it is now. To have Aurora on our team has many advantages, given that our clients can access unprecedented analytical sensitivity, which enables the quantification of pharmacokinetic (PK) profiles of drugs that have very low systemic absorption. These include predominantly local acting drugs, such as plasma concentrations of respiratory drugs (e.g., tiotropium and ipratropium), topically applied creams and ointments, and ophthalmology drops with ultra-sensitivity.”

“In addition, the quantification of drugs in low-volume matrices will also be exponentially enhanced, enabling the quantification of body fluids, where only a few microlitres can be collected, for example vaginal fluid, dried blood spots, cerebrospinal fluid, aqueous humour, synovial fluid, and epidermal micro-dialysis lysate – to name a few. The quantification of absorbed exogenous drugs into tissue, like vaginal biopsies and hair follicles, is also possible,” added Hiten. 

“And finally, multiple analyte analysis. In this case, the collected blood sample needs to be split into multiple aliquots for analysis, for example drug-drug interaction (DDI) studies with the Basel cocktail. The smaller sample volumes will allow more frequent sampling to be feasible and thus more accurate DDI interpretation,” Hiten explains.

“As a bio-analyst, one is seldom surprised. However, Aurora has already opened doors to new frontiers for our entire team and we cannot wait to do some more exploration,” says Hiten. 

To find out more about what Aurora and the FARMOVS team can do for your study, email business@farmovs.com

News Archive

UFS lecturer serves on National Forensic Oversight and Ethics Board
2015-02-13

Dr Karin Ehlers

Dr Karin Ehlers, lecturer in the Department of Genetics at the University of the Free State, was elected by the Minister of Police, Mr Nkosinathi Nhleko, to serve on the National Forensic Oversight and Ethics Board which will, among others, monitor the implementation of the provisions of the DNA Act.

Previously, when DNA evidence was collected at a crime scene, it was analysed only when requested by the prosecutor or investigator when they had found a suspect and needed confirmation. With the new DNA Act, all samples collected from violent crimes must be analysed. The profiles will be compared with a convicted offender database to see if some of the unsolved cases can be linked to these perpetrators. The reason for this is that many of these offenders are repeat offenders, and this process will increase the chances of solving cases successfully.

Serving on the Board, Dr Ehlers will also have the opportunity to contribute to proposals on:
- the improvement of practices regarding the overall operations of the National Forensic DNA Database (NFDD),
- the ethical, legal, and social implications of the use of forensic DNA profiles, and
- the training and the development of criteria for the use of familial searches.

Board members will also receive and assess complaints about alleged violations relating to the abuse of DNA samples and forensic DNA profiles and/or security breaches, and will report to complainants in respect thereof.

In 2014, when all citizens in South Africa were invited to apply for a position on the National Forensic Oversight and Ethics Board, Dr Ehlers submitted her application with a motivation on how she could contribute to the function of the Board. She is one of ten persons who were appointed to serve on the Board. “The reason I was successful was due to my involvement in the development of the UFS Forensic Sciences Programme,” Dr Ehlers said.

The capacity of the country was one of the challenges that had to be overcome for this Act to take effect. ”The UFS was able to address this problem, implementing degrees in Forensic Genetics and Forensic Sciences. With these programmes we made a real difference in the fight against crime. It is a real privilege to form part of this project,” said Dr Ehlers.

Dr Karin Ehlers serves on National Forensic Oversight and Ethics Board (read the full story)

 

For more information or enquiries contact news@ufs.ac.za

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept